Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06018896
Other study ID # PTCA199-4
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date August 25, 2023
Est. completion date August 15, 2026

Study information

Verified date August 2023
Source Fudan University
Contact Ying Yang, MD
Phone 86 21 64175590
Email yangying@fudanpci.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy of vitamin C in improving the quality of life for metastatic pancreatic cancer patients who are resistant to chemotherapy.


Description:

Pancreatic cancer is a highly lethal malignancy with a 5-year survival less than 10%. Approximately 80% of patients with pancreatic cancer are diagnosed at an advanced stage. Chemotherapy is one of the major treatments for advanced pancreatic cancer. In 2011, a trial has shown that oxaliplatin, irinotecan, fluorouracil, and leucovorin (FOLFIRINOX) was associated with a survival advantage but had increased toxicity. In 2013, the Metastatic PAncreatic Cancer Trial (MPACT) has confirmed the efficacy of gemcitabine combined with nab-paclitaxel as the first-line treatment to metastatic pancreatic cancer. However, the side-effects related to chemotherapy including anemia, hand/foot numbness, fatigue, nausea, and malnutrition have impaired the quality of life for patients. Vitamin C, also called ascorbate, is an essential nutrient for the human body. It modulates metabolism, immune reaction, collagen synthesis, and iron absorption. Some studies have shown that high-dose intravenous Vitamin C may be effective against various types of cancer. Meanwhile, medium or low dose of Vitamin C may increase iron absorption, improve anemia, alleviate pain and hand/foot numbness, and thus improve the quality of life for patients with terminal stage pancreatic cancer. The purpose of this study is to evaluate the efficacy of vitamin C on improving the quality of life for metastatic pancreatic cancer patients who are resistant to two lines of systemic chemotherapy, including gemcitabine based, fluorouracil based, or other regimen. Twenty patients who have tumor progression after receiving two lines of chemotherapy will be recruited. These patients will receive Vitamin C and the dosage is based on the concentration of baseline serum Vitamin C concentration. Quality of life, rate of hand/foot numbness, severity of pain, rate of anemia, and overall survival are measured every four weeks.


Recruitment information / eligibility

Status Recruiting
Enrollment 20
Est. completion date August 15, 2026
Est. primary completion date August 15, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - Ability to understand and the willingness to sign a written informed consent document. - Age = 18 years and = 80 years. - Eastern Cooperative Oncology Group (ECOG) performance status 0-2. - Histologically or cytologically confirmed metastatic pancreas adenocarcinoma. - Tumor progression after two lines of chemotherapy. - Adequate organ performance based on laboratory blood tests. - Presence of at least of one measurable lesion in agreement to Response Evaluation Criteria in Solid Tumours (RECIST) criteria. - The expected survival = 1 months. - Women of childbearing potential and men must agree to use adequate contraception prior to study entry and for the duration of study participation. Exclusion Criteria: - Active second primary malignancy or history of second primary malignancy. - The diagnosis was confirmed by pathology as non-adenocarcinoma of pancreas. - Inflammation of the digestive tract, including pancreatitis, cholecystitis, cholangitis, etc. - Pregnant or nursing women. - Glucose-6-phosphate dehydrogenase (G6PD) deficiency. - Severe and uncontrollable accompanying diseases that may affect protocol compliance or interfere with the interpretation of results. - Renal insufficiency or dialysis - Other serious accompanying illnesses, which, in the researcher's opinion, could seriously adversely affect the safety of the treatment. - Patients who are unwilling or unable to comply with study procedures.

Study Design


Intervention

Drug:
Ascorbate
For patients with baseline serum Vitamin C concentration < 65 µmol/L, intravenous Vitamin C 10 g × 7 days, intravenous Vitamin C 4 g × 7 days, intravenous Vitamin C 2 g × 7 days, followed by continuously 900 mg/day, three times a day, orally. For patients with baseline serum Vitamin C concentration = 65 µmol/L, continuously 900 mg/day, three times a day, orally.

Locations

Country Name City State
China Shanghai Cancer Center Shanghai Shanghai

Sponsors (1)

Lead Sponsor Collaborator
Fudan University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Quality of life (QOL) Change of QOL after every cycle of chemotherapy assessed using European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) At the end of Cycle 1 (each cycle is 28 days)
Secondary Rate of hand-foot skin reaction (HFSR) Rate of HFSR after every cycle of treatment At the end of Cycle 1 (each cycle is 28 days)
Secondary Change of numeric rating scale (NRS) Change of NRS and the administration of analgesic drugs after every cycle of chemotherapy. The range of NRS scale is 0-10 and higher scores mean a worse outcome. At the end of Cycle 1 (each cycle is 28 days)
Secondary Rate of anemia Rate of anemia after every cycle of treatment At the end of Cycle 1 (each cycle is 28 days)
Secondary Overall survival (OS) OS of subjects from date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months. At the end of Cycle 1 (each cycle is 28 days)
See also
  Status Clinical Trial Phase
Recruiting NCT04753879 - Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer. Phase 2
Completed NCT01417000 - Safety and Efficacy of Combination Listeria/GVAX Immunotherapy in Pancreatic Cancer Phase 2
Active, not recruiting NCT02975141 - Afatinib and Gemcitabine/Nab-paclitaxel in Metastatic Pancreatic Cancer Phase 1
Active, not recruiting NCT00761345 - Study of Low-Dose Fractionated Radiotherapy in Patients With Locally Advanced Metastatic Pancreatic Cancer Phase 1
Completed NCT00919282 - Gemcitabine (GFF) in Patients With Pancreatic Cancer Phase 2
Completed NCT01088815 - Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas Phase 2
Completed NCT04133155 - Retrospective Analysis of 2nd-line Nab-Paclitaxel + Gemcitabine After 1st-line FOLFIRINOX in Pancreatic Cancer
Withdrawn NCT05251038 - Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer Phase 1/Phase 2
Recruiting NCT04612530 - PANFIRE-3 Trial: Assessing Safety and Efficacy of Irreversible Electroporation (IRE) + Nivolumab + CpG for Metastatic Pancreatic Cancer Phase 1
Completed NCT03602885 - EL CENTRO: Engaging Latinos in the Center of Cancer Treatment Options N/A
Recruiting NCT05442749 - Niraparib as First Line Therapy With Metastatic Homologous Repair-deficient Pancreatic Cancer Phase 2
Recruiting NCT04222413 - Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors Phase 1
Recruiting NCT03721744 - A Study of GB201 in Combination With Weekly Paclitaxel and Low-dose Gemcitabine in Patients With Pancreatic Cancer Phase 2/Phase 3
Completed NCT03261947 - A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors Phase 2
Withdrawn NCT06017323 - Proglumide With Gemcitabine and Nab-Paclitaxel in PatientsWith Metastatic Pancreatic Ductal Adenocarcinoma Phase 1
Terminated NCT01946646 - Phase I Study of TS-1 With Concurrent Radiotherapy to Treat Pancreatic Cancer Phase 1
Completed NCT01523457 - Study of Modified FOLFIRINOX in Advanced Pancreatic Cancer Phase 2
Active, not recruiting NCT00986661 - A Study to Assess PV-10 Chemoablation of Cancer of the Liver Phase 1
Terminated NCT00726037 - A Pilot Study, Evaluating the Efficacy of Regulatory T-cell Suppression by Ontak in Metastatic Pancreatic Cancer Phase 2
Completed NCT00744640 - Gemcitabine, Oxaliplatin and Capecitabine for Advanced Pancreatic Carcinoma Phase 1/Phase 2